Dual antiplatelet therapy combining aspirin and clopidogrel is the standart care for patients WHO ave ACS or undergoing PCI according to guidelines.Itss well established that the antiplatelet response to clopidogrel varies widely among patients.Patients displaying little attenuation of platelet reactivity under therapy are recognized as clopidogrel resistant.Different mechanisms responsible for the phenomenon of clopidogrel resistance have been suggested with genetic polymorphisms being one of the most widely studied.
Keywords: clopidogrel, genetic polimorphism, coronary artery diseaseCopyright © 2025 Archives of the Turkish Society of Cardiology